Latest Breaking News On - நாஸ்டாக் பயோடெக் குறியீட்டு - Page 3 : comparemela.com

DGAP-News: BB BIOTECH AG / Key word(s): Annual Results/Dividend BB BIOTECH AG: Vaccines leading the way out of the pandemic - increased dividend of CHF 3.60 proposed 22.01.2021 / 07:00 Media release as of January 22, 2021 Portfolio of BB Biotech AG as of December 31, 2020 Vaccines leading the way out of the pandemic - increased dividend of CHF 3.60 proposed BB Biotech performed well in 2020 in a volatile market environment. The biotech sector made significant strides, leading the effort against the SARS-CoV-2 virus pandemic through approved mRNA vaccines and therapeutic antibodies. M&A activity picked up substantially in H2 2020, further driving solid performance as the year came to a close. The fourth quarter alone drove a portfolio gain of 20.6% in CHF, 20.4% in EUR and 25.5% in USD for BB Biotech - reflecting a net gain of CHF 665 mn. In parallel, the share price appreciated by 10.9% in CHF and 9.0% in EUR. BB Biotech exited four holdings and added three new holdings in th

United statesWhite houseDistrict of columbiaNeurocrine biosciencesJeffreyd zientsTanja chicherioClaude mikkelsenBristol myers squibbSilvia siegfried schanzXavier becerraThomas eggerMaria grazia iten alderuccioInvestment management team of bellevue assetScholar rock holdingAlnylam pharmaceuticalsGeneration bio co